The challenges of treating peripheral arterial disease

Vascular Medicine

Volumn 8, Issue 2, 2003, Pages 109-114

  Kügler, Christian F A ^a   Rudofsky, Gottfried ^b  

^a Herz Kreislauf Klinik Bevensen   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Comorbidity; Cost efficiency; Exercise therapy; Life quality; Percutaneous transluminal angioplasty (PTA); Peripheral arterial disease; Preventive measures; Therapeutic strategies; Vascular surgery; Vasoactive drugs

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BUFLOMEDIL; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAFTIDROFURYL; PENTOXIFYLLINE; PROSTAGLANDIN; PROSTAGLANDIN E1; TICLOPIDINE; VASOACTIVE AGENT;

ADJUVANT THERAPY; ARTERY DISEASE; ARTERY OCCLUSION; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLAUDICATION; CLINICAL TRIAL; CONSERVATIVE TREATMENT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE CONTROL; DISEASE COURSE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; FEMOROPOPLITEAL BYPASS; FOLLOW UP; HEALTH CARE COST; HEART DISEASE; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; KINESIOTHERAPY; LIMB ISCHEMIA; LONG TERM CARE; LOW DRUG DOSE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; QUALITY OF LIFE; RESTENOSIS; REVASCULARIZATION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SURGICAL TECHNIQUE; TREATMENT INDICATION;

COST-BENEFIT ANALYSIS; HUMANS; LIFE STYLE; PERIPHERAL VASCULAR DISEASES; QUALITY OF LIFE; RISK FACTORS;

EID: 0141719327     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x03vm478ra     Document Type: Review

References (91)

1. Kannel WB. The demographics of claudication and the aging of the American population. Vasc Med 1996; 1: 60-64.
2. Olshansky SJ, Rudberg MA, Carnes BA, Cassel CK, Brody J. Trading-off longer life for worsening health: The expansion of morbidity hypothesis. J Health Age 1991; 3: 194-216.
3. Matsi PJ, Manainen HI, Sahonen MT. Chronic critical limb ischemia: Prospective trial of angioplasty with 1-36 month of follow-up. Radiology 1993; 188: 381-87.
4. Arfvidsson B, Karlsson J, Dahllof AG. The impact of intermittent claudication on quality of life evaluated by the Sickness Impact Profile technique. Eur J Clin Invest 1993; 23: 741-45.
5. Smith I, Franks PJ, Greenhalgh RM, Poulter NR, Powell JT. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischemia. Eur J Vasc Endovasc Surg 1996; 11: 402-408.
6. Hirsch AT, Treat-Jacobson D, Lando HA, Hatsukami DK. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. Vasc Med 1997; 2: 43-51.
7. Pfaffenbarger RS, Hyde RT, Wing AL, Lee IM, Jung DL, Kampert JB. The association of changes in physical activity level and other life style characteristics with mortality among men. N Engl J Med 1993; 328: 538-45.
8. Hakim AA, Petrovitch H, Burchfiel CM et al. Effects of walking on mortality among nonsmoking retired men. N Engl J Med 1998; 338: 94-9.
9. Fries JF, Singh G, Morfeld D, Hubert HB, Lane NE, Brown BW. Running and the development of disability with age. Ann Intern Med 1994; 121: 502-509.
10. Vita AJ, Terry RB, Hubert HB, Fries JF. Aging, health risk, and cumulative disability. N Engl J Med 1998; 338: 1035-41.
11. Staessen JA, Fagard R, Thijs L. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757-64.
12. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
13. Shepherd J, Cobbe SM, Ford I et al. for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 331: 301-307.
14. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Lancet 2001; 357: 89-95.
15. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
16. The Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89.
17. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
18. Janzon L, Bergqvist D, Boberg J. Prevention of myocardial infarction and stroke in patients with intermittent claudication: Effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicenter Study. J Intern Med 1990; 227: 310-18.
19. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348: 1329-39.
20. Eccles M, Freemantle MN, Mason J. North of England evidence based guideline development project: Guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England aspirin guideline development. BMJ 1998; 316: 1303-309.
21. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ 1994; 308: 159-68.
22. Becquemin JP. Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs. N Engl J Med 1997; 337: 1726-31.
23. Hess H, Deichsel G, Mietaschk A. Drug-induced inhibition of platelet function delays progression of peripheral arterial occlusive disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; I: 415-19.
24. Goldhaber SZ, Manson JE, Stampfer MJ, LaMotte F, Rosner B, Buring JE. Low-dose aspirin and subsequent peripheral arterial surgery in the physicians' health study. Lancet 1992; 340: 143-45.
25. Duffield RGM, Lewis B, Miller NE, Jamieson CW, Brunt JN, Colchester AC. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis: A randomised controlled trial. Lancet 1983; 2: 639-42.
26. Olsson AG, Ruhn G, Erikson U. The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidemia: A non-randomized controlled study. J Intern Med 1990; 227: 381-90.
27. Blankenhorn DH, Azen SP, Crawford DW. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991; 83: 438-47.
28. DeGroot E, Jukema JW, Van Boven AJ, Reiber JH, Zwinderman AH, Lie KI. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: A report for the Regression Growth Evaluation Statin Study. Am J Cardiol 1995; 76: 40C-46C.
29. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes. Lancet 1998; 352: 837-53.
30. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 352: 854-65.
31. Solomon SA, Ramsay LE, Yee WW, Parnell L, Morris-Jones W. Beta-blockade and intermittent claudication: Placebo-controlled trial of atenolol and nifedipine and their combination. BMJ 1991; 303: 1100-104.
32. Cachovan M. Methods and results of controlled walking training in patients with peripheral arterial occlusive disease. Z Ärztl Fortbildung Qualitätssicherung 1999; 93: 626-32.
33. Chong PF, Golledge J, Greenhalgh RM, Davies AF. Exercise therapy or angioplasty? A summation analysis. Eur J Vasc Endovasc Surg 2000; 20: 4-12.
34. Hiatt WR, Regensteiner JG, Hargarter ME, Wolfel EE, Brass EP. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990; 81: 602-609.
35. Izquierdo-Porrera AM, Gardner AW, Powell CC, Katzel LI. Effects of exercise rehabilitation on cardiovascular risk factors in older patients with periperal arterial oclusive disease. J Vasc Surg 2000; 31: 670-76.
36. De La Haye R, Diehm C, Blume J et al. An epidemiologic study of the value and limits of physical therapy/exercise therapy in Fontaine stage II arterial occlusive disease. VASA 1992; Suppl 38: 1-40.
37. Gillings DB. Pentoxifylline and intermittent claudication: Review of clinical trials and cost-effectiveness analyses. J Cardiovasc Pharmacol 1995; 25: S44-50.
38. Lehert P, Riphagen FE, Gamand S. The effect of naftidrofuryl on intermittent claudication: A metaanalysis. J Cardiovasc Pharmacol 1990; 16 (Suppl 3): 81-86.
39. Spengel F, Brown TM, Poth J, Lehert P. Naftidrofuryl can enhance the quality of life in patients with intermittent claudication. VASA 1999; 28: 207-12.
40. Kieffer E, Bahnini A, Mouren X, Gamand S. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol 2001; 20: 58-65.
41. Dawson DL, Cutler BS, Meissner MH, Strandness DE. Cilostazol has beneficial effects in treatment of intermittent claudication: Results from a multicenter, randomized, prospective double-blind trial. Circulation 1998; 98: 678-86.
42. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treatment of intermittent claudication. Am J Med 2000; 109: 523-30.
43. Dormandy JA. Prostanoid drug therapy for peripheral arterial occlusive disease - The European experience. Vasc Med 1996; 1: 155-58.
44. Diehm C, Balzer K, Bisler H. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: Results of a multicenter placebo-controlled double-blind trial. J Vasc Surg 1997; 25: 537-44.
45. Mangiafico RA, Messina R, Attina T, Dell'Árte S, Giuliano L, Malatino LS. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication. Angiology 2000; 51: 441-49.
46. Scheffler P, De La Hamette D, Gross J, Mueller H, Schieffer H. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training. Circulation 1994; 90: 818-22.
47. Lehart P, Comte S, Gamand S. Naftidrofuryl in intermittent claudication: A retrospective analysis. J Cardiovasc Pharmacol 1994; 23 (Suppl 3): S48-S52.
48. Klimm HD, Huppertz E. Mortalitätsbetrachtungen bei pAVK-Patienten einer angiologischen Spezialambulanz mit und ohne vasoaktive Medikation - Eine retrospektive Untersuchung. VASA 1996; 45 (Suppl): 1-5.
49. Rutherford RB, Flanigan DP, Gupta SK et al. Suggested standards for reports dealing with lower extremity ischemia. J Vasc Surg 1986; 4: 80-94.
50. TASC. Management of peripheral arterial disease. Int Angiol 2000; 19 (Suppl 1): 101-17.
51. Standards of Practice Committee of the Society of Cardiovascular and Interventional Radiology. Guidelines for percutaneous transluminal angioplasty. Radiology 1990; 177: 619-26.
52. Wilson SE, Wolf GL, Cross AP. Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis: Report of a prospective randomized trial in a selected group of patients. J Vasc Surg 1989; 9: 1-9.
53. Holm J, Arfvidsson B, Jivegard L, Lundgren F, Lungholm K, Schersten T. Chronic lower limb ischemia: A prospective randomized controlled study comparing the 1-year results of vascular surgery and percutaneous transluminal angioplasty (PTA). Eur J Vasc Surg 1991; 5: 517-22.
54. Cook TA, O'Regan M, Galland RB. Quality of life following percutaneous transluminal angioplasty for claudication. Eur J Vasc Endovasc Surg 1996; 11: 191-94.
55. Feinglass J, McCarthy WJ, Slavensky R. Effect of lower extremity blood pressure on physical functioning in patients with intermittent claudication. J Vasc Surg 1996; 24: 503-12.
56. Kügler CFA, Rudofsky G. Welche Faktoren beeinflussen periinterventionell die Lebensqualität bei Patienten mit symptomatischer pAVK? VASA 2002; 31 (Suppl 61): 75.
57. Reifler DR, Feinglass J, Slavensky R, Martin GJ, Manheim L, McCarthy WJ. Functional outcomes for patients with intermittent claudication: Bypass surgery versus angioplasty versus noninvasive management. J Vasc Med Biol 1994; 5: 203-11.
58. Feinglass J, McCarthy WJ, Slavensky R, Manheim LM, Martin GJ. Functional status and walking ability after lower extremity bypass grafting or angioplasty for intermittent claudication: Results from a prospective outcomes study. J Vasc Surg 2000; 31: 93-103.
59. Lundgren F, Dahlloff A, Lundholm K, Schersten T, Volkman R. Intermittent claudication: Surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency. Ann Surg 1989; 209: 346-55.
60. Gelin J, Jivegard L, Taft C et al. Treatment efficacy of intermittent claudication by surgical intervention, supervised physical exercise training compared to no treatment in unselected randomised patients I: One year results of functional and physiological improvements. Eur J Vasc Endovasc Surg 2001; 22: 107-13.
61. Taft C, Karlsson J, Gehlin J et al. Treatment efficacy of intermittent claudication by invasive therapy, supervised physical exercise training compared to no treatment in unselected randomised patients II: One-year results of health-related quality of life. Eur J Vasc Endovasc Surg 2001; 22: 114-23.
62. Perkins JM, Collin J, Creasy TS, Fletcher EW, Morris PJ. Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial. Eur J Vasc Endovasc Surg 1996; 11: 409-13.
63. Whyman MR, Fowkes FG, Kerracher EM, Gillespie IN, Lee AJ, Housley E, Ruckley CV. Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomized controlled trial. J Vasc Surg 1997; 26: 551-57.
64. Gailer H, Grüntzig AR, Zeitler E. Late results after percutaneous transluminal angioplasty of iliac and femoropopliteal obstructive lesions - A cooperative study. In: Dotter CT, Grüntzig AR, Schoop W, Zeitler E eds. Percutaneous Transluminal Angioplasty. Berlin: Springer, 1983: 215-8.
65. Becker GJ, Katzen BT, Dake MD. Noncoronary angioplasty. Radiology 1989; 170: 921-40.
66. Veith FJ, Gupta SK, Ascer E. Six year prospective multicenter randomized comparison of autologous saphenous vein and expanded PTFE grafts in infrainguinal arterial J Vasc Surg 1986; 3: 104-14.
67. Gallino A, Mahler F, Probst P, Nachbur B. Percutaneous transluminal angioplasty of the lower limbs - 5 year follow-up. Circulation 1984; 70: 619-23.
68. Johnston WK, Rae M, Hogg-Johnston SA et al. Five-year results of a prospective study of percutaneous transluminal angioplasty. Ann Surg 1987; 206: 403-13.
69. Peterkin GA, La Morte WW, Menzolan JO. Runoff resistance and early graft failure in infrainguinal bypass surgery. Arch Surg 1988; 123: 1199-201.
70. Capek P, McLean GK, Berkowitz HD. Femoropopliteal angioplasty. Factors influencing long-term success. Circulation 1991; 83: (Suppl 1): 170-80.
71. Holdsworth JD. Five-year vascular audit from a district hospital. Br J Surg 1991; 78: 601-606.
72. Klag MJ, Whelton PK, Seidler AJ. Decline in US stroke mortality. Demographic trends and antihypertensive treatment. Stroke 1989; 20: 14-21.
73. Hunink MGM. The recent decline in mortality from coronary heart disease, 1980-1990. JAMA 1997; 277: 535-42.
74. Gershlick AH. Endovascular manipulation to restrict restenosis. Vasc Med 1998; 3: 177-88.
75. Lubitz J, Beebe J, Baker C. Longevity and Medicare expenditures. N Engl J Med 1995; 332: 999-1003.
76. Jansen RM, De Vries SO, Cullen KA, Donaldson MC, Hunink MG. Cost-identification analysis of revascularization procedures on patients with peripheral arterial occlusive disease. J Vasc Surg 1998; 28: 617-23.
77. Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, DeVries J, Harrington DP. Revascularization for femoropoliteal disease: A decision and cost-effectiveness analysis. JAMA 1995; 274: 165-71.
78. Rudofsky G, Van Laak HH. Treatment costs of peripheral arterial occlusive disease in Germany: A comparison of costs and efficacy. J Cardiovasc Pharmacol 1994; 23 (Suppl 3): S22-5.
79. Singh S, Evans L, Datta D, Gaines P, Beard JD. The costs of managing lower limb-threatening ischaemia. Eur J Vasc Endovasc Surg 1996; 12: 359-62.
80. Ollendorf DA, Kotsanos JG, Wishner WJ et al. Potential economic benefits of lower extremity amputation prevention strategies in diabetes. Diabetes Care 1998; 21: 1240-45.
81. Murphy TP. Medical outcome studies in peripheral vascular disease. J Vasc Interv Radiol 1998; 9: 879-89.
82. Stone NJ. The clinical and economic significance of atherosclerosis. Am J Med 1996; 101(4A): 4A6S-9S.
83. Superko HR. Sophisticated primary and secondary atherosclerosis prevention is cost effective. Can J Cardiol 1995; 11 (Suppl C): 35C-40C.
84. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996; 78: 409-414.
85. Gotto AM Jr. Assessing the benefits of lipid lowering therapy. Am J Cardiol 1998; 82: 2M-4M.
86. Wolf GL, McLean G. Comparison of the costs of bypass surgery and transluminal angioplasty for peripheral vascular disease. Radiology 1984; 1: 237-39.
87. Jeans WD, Danton RM, Baird RN, Horrocks M. A comparison of the costs of vascular surgery and balloon dilatation in lower limb ischaemic disease. Br J Radiol 1986; 59: 453-56.
88. Taylor P, Beard JD. Economics of vascular surgery. Br J Hosp Med 1997; 58: 406-409.
89. Dyet JF, Shaw JW, Cook AM, Nicholson AA. The use of the Wallstent in aorto-iliac vascular disease. Clin Radiol 1993; 48: 227-31.
90. Williams JB, Watts PW, Nguyen VA, Peterson CL. Balloon angioplasty with intraluminal stenting as the initial treatment modality in aorto-iliac occlusive disease. Am J Surg 1994; 168: 202-204.
91. Bosch JL, Tetteroo E, Mali WP, Hunink MG. Iliac arterial occlusive disease: Cost-effectiveness analysis of stent placement versus percutaneous transluminal angioplasty. Dutch Iliac Stent Trial Study Group. Radiology 1998; 208: 641-48.